Understanding the Coordinated Effects of PPARs on Lipid Metabolism Using Microarrays

• Published in: Understanding Lipid Metabolism with Microarrays and Other Omic Approaches pp. 249 - 263
• Main Authors: Kersten, Sander, Escher, Pascal, Tafuri, Sherrie, Wahli, Walter
• Format: Book Chapter
• Language: English
• Published: United Kingdom CRC Press 2005; Taylor & Francis Group; Marcel Dekker
• Edition: 1
• Subjects: Biochemistry; Chair Nutrition Metabolism and Genomics; Food & beverage technology; Genetics (non-medical); HNE Nutrition, Metabolism and Genomics; HNE Voeding, Metabolisme en Genomics; Nutrition, Metabolism and Genomics; VLAG; Voeding, Metabolisme en Genomica; HMG CoA Synthase; LC PUFA Supplementation; 3T3 L1 Adipogenesis; MAPK Phosphatase; PPAR Ligand; 3T3 L1 Fibroblast; Nuclear Hormone Receptors; PPAR Agonist; SREBP-1 Target Gene; Protein Tyrosine Phosphatase 1B; Adipogenic Marker Genes; SREBP-1 Target; High Throughput Gene Expression Profiling; Glycerol-3 Phosphate Acyltransferase; PTP1B; Factor SREBP-1; Pyruvate Dehydrogenase Kinase; PPAR Isotype; CEA Protein; Acetyl CoA; PTP1B Expression; DNA Transcription
• ISBN: 9780824758110; 0824758110
• DOI: 10.1201/9781420030921-11

The application of high throughput gene expression profiling via microarrays is slowly causing a revolution in biomedical science. Until recently determining the expression of numerous genes at once was a wild fantasy; nowadays, however, the expression monitoring of thousands of genes simultaneously has become a routine procedure. Despite its relatively high cost, an increasing number of researchers, in both industry and academia, are able to benefit from the power of this technology. One important area that was predicted to profit immensely from microarray technology is drug development and validation. Although within the pharmaceutical industry huge progress has been made in the implementation of DNA microarrays into drug development, many obstacles still need to be overcome, some of which are alluded to in this paper.